Crossmark

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Crossref DOI link: https://doi.org/10.1038/s41598-024-60864-3

Published Online: 2024-05-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akenroye, Ayobami

Nopsopon, Tanawin

Hacker, Jonathan J.

Laidlaw, Tanya M.
Funding

Funding for this research was provided by:

American Lung Association/American Thoracic Society/CHEST Foundation Respiratory Health Equity Research Award

Harvard Medical School Diversity, Inclusion, and Community Partnership (HMS DICP) Faculty Fellowship

National Institute of Allergy and Infectious Diseases (U19-AI095219)
License Information

Text and Data Mining valid from 2024-05-06

Version of Record valid from 2024-05-06
More Information

Article History

Received: 4 November 2023

Accepted: 29 April 2024

First Online: 6 May 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below